What are GLP-1 receptor agonists?

GLP-1 receptor agonists are compounds that activate the GLP-1 (glucagon-like peptide-1) receptor, which is involved in glucose regulation and appetite signalling.

In research literature, GLP-1 activity is associated with:

• Increased glucose-dependent insulin secretion
• Reduced glucagon secretion, context-dependent
• Slower gastric emptying
• Changes in appetite and satiety signalling

Why "agonist" and not "GLP-1"

Native GLP-1 is useless as a drug: DPP-4 degrades it within roughly two minutes of release. Every clinically useful compound in this class is therefore an analog engineered to survive that enzyme — and often to bind albumin as well, pushing the half-life from minutes to days.

That engineering is what separates the generations. Early agonists required twice-daily administration; later ones with albumin-binding modifications moved to weekly.

Glucose-dependent is the key phrase

The insulin effect scales with blood glucose rather than firing regardless of it. That dependency is why the mechanism behaves differently from insulin itself.

Beyond GLP-1 alone

Newer compounds add other receptors — GIP, or GIP plus glucagon. See how the three receptors differ and the GLP-1 and metabolic category.

Research use only. Not medical advice.